Overview
Founded in 2020, QuantHealth has simulated more than 600 clinical trials across 30 indications, achieving up to 90% predictive accuracy. This track record has made QuantHealth a trusted partner to the world's leading biopharma companies.
As the leader in clinical trial simulations, QuantHealth is accelerating the industry's move toward simulation-first clinical development — an approach in which life sciences and biotechnology companies test, optimize, and de-risk their clinical trials through AI-driven simulation before a patient is enrolled or capital is deployed.
QuantHealth's simulation-first platform supports decision-making across every stage of drug development, from clinical trial planning and indication selection to drug in-licensing and market positioning using simulated outcomes rather than historical data.
Redefining Clinical Development
Most predictive tools in clinical development work backward by analyzing trial data after patients have already been enrolled. QuantHealth works differently by predicting how a patient will respond to treatment before a trial begins, before a patient is enrolled, and before capital is deployed.
That distinction redefines clinical development: instead of discovering a trial's opportunities or risks after they've materialized, with QuantHealth, biopharma can test and de-risk decisions through simulation while there's still time to make adjustments.
QuantHealth is helping to make clinical development predictable by replacing costly trial-and-error with evidence-based certainty, so effective treatments reach patients faster and with less risk.
Our Award-Winning Platform
Proud to Partner with
Proudly Supported by
Leadership
The QuantHealth executive team embodies talent, expertise, and dedication. Comprising a large and diverse group of professionals, we bring together specialists from a wide array of disciplines, including AI, data science, biology, medicine, bioinformatics, mathematics, software engineering, product management, immunology, pharmacology, and epidemiology.
Our team features backgrounds from leading academic institutions and top-tier industry roles, ensuring that we operate at the forefront of innovation and excellence. With 36% of our team holding PhDs or MDs and 75% possessing advanced degrees, we are not just highly qualified — we are passionate about what we do: revolutionizing healthcare and make a profound impact on the future of medicine.
Beca, MD, PhD
Advisory Board
